GlassScriptPhysician profile
Claire Kramer
NPI 1699428300
$13,099.19
in general payments reported to CMS, 2019-2025
44 companies · $4,248 in 2025
The $4,248 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,642 · 2023: $2,948 · 2024: $3,260 · 2025: $4,248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $365.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,092.30 |
| Education | $364.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $3,231.55 | 2022-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $2,010.18 | 2022-2025 | |
| Inspire Medical Systems, INC. | $1,631.61 | 2022-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,103.34 | 2022-2025 | Airsupra, Tezspire, Breztri |
| Axsome Therapeutics, INC. | $1,064.93 | 2023-2025 | Sunosi |
| Glaxosmithkline, LLC. | $467.19 | 2023-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Avadel Cns Pharmaceuticals, LLC | $327.16 | 2023-2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.52 | 2022-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Regeneron Healthcare Solutions, INC. | $255.17 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $254.01 | 2024-2025 | Zepbound, Mounjaro |
| Genzyme Corporation | $223.06 | 2022-2024 | |
| Amgen INC. | $218.60 | 2022-2025 | Tezspire, Tavneos |
| Zoll Respicardia, INC. | $189.95 | 2023-2025 | Remede System |
| Dexcom, INC. | $152.65 | 2025 | Dexcom G6 Transmitter |
| Insmed, INC. | $137.55 | 2023-2025 | Arikayce |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $129.75 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $125.31 | 2022-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $113.32 | 2024-2025 | Horizant, Alvesco |
| Abbvie INC. | $105.21 | 2023 | |
| Vertex Pharmaceuticals Incorporated | $92.64 | 2025 | |
| Genentech USA, INC. | $91.70 | 2022-2025 | Xolair |
| Mylan Specialty L.P. | $90.95 | 2022-2023 | Yupelri |
| Grifols USA, LLC | $85.78 | 2023-2025 | Prolastin-C Liquid |
| Viatris Specialty LLC | $80.36 | 2025 | Yupelri |
| Xeris Pharmaceuticals, INC. | $77.15 | 2024-2025 | Keveyis, Recorlev |
| Verona Pharma, INC. | $59.83 | 2025 | Ohtuvayre |
| Ascendis Pharma Endocrinology INC | $55.97 | 2025 | Yorvipath |
| Philips North America LLC | $53.99 | 2024-2025 | (7999) Src Undivided, Patient Interface Software, (Ak6) Vest Therapy |
| Cequr Corporation | $38.63 | 2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $32.99 | 2022-2024 | |
| Actelion Pharmaceuticals US, INC. | $32.89 | 2023-2024 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $30.76 | 2024 | Glassia |
| Inogen, INC. | $27.67 | 2022-2024 | |
| Electromed, INC. | $26.37 | 2025 | Smartvest |
| Beta Bionics, INC. | $22.44 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Mannkind Corporation | $20.61 | 2025 | |
| Baxter Healthcare | $20.59 | 2025 | Hillrom - Vest System Model 205 Acute Care |
| Resmed Corp | $18.18 | 2024 | |
| Ethicon US, LLC | $15.63 | 2022 | |
| Medtronic, INC. | $15.26 | 2025 | Propel |
| Vifor Pharma, INC. | $14.49 | 2025 | Veltassa |
| Pulmonx Corporation | $13.95 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Covis Pharma Gmbh | $13.77 | 2022 | |
| Corcept Therapeutics | $13.53 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Kramer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.